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background:  Annulus-sparing (AS) repair of tetralogy of Fallot (TOF) carries a potential cost of increased reoperation for re-stenosis and unproven 
benefits on RV geometry.
methods:  Primary TOF repairs (N=458) between 2000 and 2012 were studied. Prior palliation was rare (invariably RVOT stent; N=16).
results:  Repair was mean age 180 days: AS in 297 (65%), trans-annular patch (TAP) in 137 (30%) and conduit in 24 (5%). Intra-op revisions (for 
residual stenosis) were required in 135 (29%). In the AS group, if reoperation was required for RVOT re-stenosis, the strategy “failed” (14/297, 5%). 
Failed strategies were linked to smaller pre-op PV (5.6 v 7.5 mm, P=.01), RVEDD (0.9 v 1.2 cm, P=.04) and TV dimensions (1.2 v 1.4 cm, P=.04). 
Failed strategies were significantly related to smaller RVOT (mean 9 vs 10.5 mm, P=.01) and higher RVSP (mean 56 vs 45 mmHg, P=.002) measured 
intra-op after repair (figure). Repeated measures analysis of 2,103 RVEDD and 2,009 QRS measurements demonstrated accelerated RV dilatation 
in TAP versus non-TAP P<.0001, figure), but no differences in QRS. Only 4 deaths have occurred (survival 99%). Surgical re-intervention to a TAP was 
occasionally required (5/137, 4%) and this rate was not different to the AS group (P=.83).
conclusions:  The cost of pursuing an AS approach seem negligible. PV enlargement to >10 mm and RVSP <50 should equate to low risk of 
restenosis. Faster RV dilatation after TAP seen herein supports AS strategy. Whether the AS strategy will translate into reduced PVR rate is not known.
 
